Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김규보 | * |
dc.contributor.author | 박경란 | * |
dc.date.accessioned | 2018-12-07T16:30:20Z | - |
dc.date.available | 2018-12-07T16:30:20Z | - |
dc.date.issued | 2017 | * |
dc.identifier.issn | 1598-2998 | * |
dc.identifier.other | OAK-21498 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/247281 | - |
dc.description.abstract | Purpose The purpose of this study was to evaluate the impact of postmastectomy radiotherapy (PMRT) on loco-regional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) in pT1-2N1 patients treated with taxane-based chemotherapy. Materials and Methods We retrospectively reviewed the medical data of pathological N1 patients who were treated with modified radical mastectomy and adjuvant taxane-based chemotherapy in 12 hospitals between January 2006 and December 2010. Results We identified 714 consecutive patients. The median follow-up duration was 69 months (range, 1 to 114 months) and the 5-year LRRFS, DFS, and OS rates were 97%, 94%, and 98%, respectively, in patients who received PMRT (PMRT [+]). The corresponding figures were 96%, 90%, and 96%, respectively, in patients who did not receive PMRT (PMRT [-]). PMRT had no significant impact on survival. Upon multivariable analysis, only the histological grade (HG) was statistically significant as a prognostic factor for LRRFS and DFS. In a subgroup analysis of HG 3 patients, PMRT (+) showed better DFS (p=0.081). Conclusion PMRT had no significant impact on LRRFS, DFS, or OS in pT1-2N1 patients treated with taxane- based chemotherapy. PMRT showed a marginal benefit for DFS in HG 3 patients. Randomized studies are needed to confirm the benefit of PMRT in high risk patients, such as those with HG 3. © 2017 by the Korean Cancer Association. | * |
dc.language | English | * |
dc.publisher | Korean Cancer Association | * |
dc.subject | Breast neoplasms | * |
dc.subject | Disease-free survival | * |
dc.subject | Radiotherapy | * |
dc.subject | Recurrence | * |
dc.subject | Survival | * |
dc.subject | Taxane | * |
dc.title | Postmastectomy radiotherapy in patients with pT1-2N1 breast cancer treated with taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418) | * |
dc.type | Article | * |
dc.relation.issue | 4 | * |
dc.relation.volume | 49 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 927 | * |
dc.relation.lastpage | 936 | * |
dc.relation.journaltitle | Cancer Research and Treatment | * |
dc.identifier.doi | 10.4143/crt.2016.508 | * |
dc.identifier.wosid | WOS:000413001500008 | * |
dc.identifier.scopusid | 2-s2.0-85030762872 | * |
dc.author.google | Kim Y.-J. | * |
dc.author.google | Park W. | * |
dc.author.google | Ha B. | * |
dc.author.google | Park B. | * |
dc.author.google | Joo J. | * |
dc.author.google | Kim T.H. | * |
dc.author.google | Park I.H. | * |
dc.author.google | Lee K.S. | * |
dc.author.google | Lee E.S. | * |
dc.author.google | Shin K.H. | * |
dc.author.google | Kim H. | * |
dc.author.google | Yu J.I. | * |
dc.author.google | Choi D.H. | * |
dc.author.google | Huh S.J. | * |
dc.author.google | Wee C.W. | * |
dc.author.google | Kim K. | * |
dc.author.google | Park K.R. | * |
dc.author.google | Kim Y.B. | * |
dc.author.google | Ahn S.J. | * |
dc.author.google | Lee J.H. | * |
dc.author.google | Kim J.H. | * |
dc.author.google | Chun M. | * |
dc.author.google | Lee H.-S. | * |
dc.author.google | Kim J.S. | * |
dc.author.google | Cha J. | * |
dc.contributor.scopusid | 김규보(8213302900) | * |
dc.contributor.scopusid | 박경란(14040340300;57203047823;57207108839;57308917900) | * |
dc.date.modifydate | 20240222162403 | * |